What Is Duchenne Muscular Dystrophy?

An accomplished businessman, Edgar Alacan serves as a member of the board of directors of PietrosFight.org. The nonprofit organization aims to raise funds to support research efforts to find a cure for Duchenne Muscular Dystrophy (DMD). Since 2013, Edgar Alacan has assisted PietrosFight.org, which is dedicated to increasing awareness about DMD.

DMD is a fatal genetic condition that most frequently affects male children. Approximately 300,000 boys around the world - and 20,000 in the Unites States - are affected by the disease, which causes the muscles to deteriorate. Children with DMD require a wheelchair by the age of 12.

In addition, males do not survive beyond their mid-20s. During the early stages, movement becomes difficult, and eventually the heart and respiratory muscles begin to fail. The condition has no cure. Recently, gene-based therapies have shown promise in the fight against DMD. Approaches include RNA-based technology, gene replacement, and drug-based solutions. 

Jet.com’s Assure Safety Standards Exceed Federal Requirements

The co-founder of Jets.com, Edgar Alacan heads strategic direction for the firm, which employs 50 individuals and achieves over $40 million in annual sales. Under Edgar Alacan’s leadership, Jets.com offers a number of private jet charter options and upholds an unwavering commitment to safety.

While all private jet owners follow a set of Federal Aviation Administration regulations known as FAR 91, Jets.com goes above and beyond to implement its own set of Assure Safety Standards. The company’s proprietary safety program outlines company rules related to drug and alcohol testing foo pilots, required pre-employment testing, and random and periodic testing once pilots are hired.

Assure Safety Standards also maintain runway length requirements that ensure aircraft can land within 80 percent of the runway length, and strictly regulate how long crew members can fly and how long they must rest between flights. Additionally, Jet.com’s safety standards require compliance with the Pilot Records Improvement Act, and prohibit aircraft from landing at airports without weather-reporting facilities.

Falcon 900EX vs. Falcon 50 EX – Two Popular Planes at Jets.com

With a business administration degree from Brooklyn College, Edgar Alacan has been responsible for the strategic management and long-term growth of Jets.com since 2008. At Jets.com, Edgar Alacan oversees a staff of more than 40 people, while establishing and maintaining client relationships. The New York-based company provides private travel services using jets such as the Falcon 900EX and the Falcon 50 EX.

The Falcon 900EX and Falcon 50 EX are, respectively, part of the heavy group category and the super-mid jet class. While the 50 EX has a seating capacity of nine passengers, the 900EX seats up to 14 passengers in total.

Both are spacious aircraft for trips that require additional storage. The Falcon 50 EX features 115 cubic feet of baggage capacity and the Falcon 900EX has an additional 12 cubic feet.

The comfortable Falcon 50 EX comes with a sizeable stand-up cabin and a full-service mini galley, and supple leather seats. The Falcon 900EX cabin stands at 6.2 feet high, 33.2 feet long, and 7.7 feet wide, with various configurations and layouts available.

Pietro’s Fight Holds Fourth Annual 5K Event

With almost three decades of experience in the aviation industry, Edgar Alacan serves as the managing director of jets.com, a firm that he co-founded in 2008. Alongside this, Edgar Alacan supports several nonprofits, such as Pietro’s Fight, which raises awareness of and funds for research into Duchenne muscular dystrophy (DMD).

The organization recently held an event, called “Pietro’s Fight to the Finish Line,” which took place on September 24 and raised funds for the organization and DMD research. Dayna Scarso, who co-founded the charity after her son, Pietro, was diagnosed with the disease, noted that there was a large turnout for the event.

In addition, she highlighted that members of the nonprofit, as well as other event participants, were celebrating the news that Exondys 51 was approved for DMD patients by the Food and Drug Administration. Also known as Eteplirsen, it is the first drug to be approved to treat muscular dystrophy patients, a move that was welcomed by many organizations.